Table 3.
The predictive value of PCDH8 methylation for the recurrence-free survival in non muscle invasive bladder cancer (n = 233)
| Variable |
Univariate analysis |
Multivariate analysis |
||||
|---|---|---|---|---|---|---|
| HR | 95% CI | P | HR | 95% CI | P | |
| PCDH8 methylation (M vs. U) |
7.083 |
2.576-14.621 |
<0.0001 |
4.739 |
1.872-12.053 |
<0.0001 |
| Age (>65 vs. ≦65) |
1.241 |
0.768-5.724 |
0.7931 |
|
|
|
| Sex (Male vs. Female) |
0.926 |
0.753-3.761 |
0.8541 |
|
|
|
| Number (Multiple vs. Single) |
1.411 |
0.674-12.653 |
0.7244 |
|
|
|
| Size (>3 cm vs. ≤3 cm) |
1.537 |
0.687-10.431 |
0.7196 |
|
|
|
| Grade (G3 vs. G1/G2) |
5.067 |
1.933-10.763 |
0.0006 |
2.055 |
1.644-8.431 |
0.0137 |
| Stage (T1 vs. Ta) | 2.073 | 1.027-9.754 | 0.0176 | 1.371 | 0.824-6.084 | 0.0735 |
HR: Hazard Ratio; M: Methylated; U: unmethylated.